How hyperglycemia promotes atherosclerosis: molecular mechanisms

被引:363
作者
Aronson, Doron [1 ]
Rayfield, Elliot J. [2 ,3 ]
机构
[1] Rambam Med Ctr, Div Cardiol, IL-31096 Haifa, Israel
[2] Mt Sinai Sch Med, New York, NY 10029 USA
[3] Rockefeller Univ Hosp, New York, NY 10021 USA
关键词
Amadori Product; Complement Regulatory Protein; Nonenzymatic Glycosylation; Vascular Wall Cell; Glycoxidation Product;
D O I
10.1186/1475-2840-1-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both type I and type II diabetes are powerful and independent risk factors for coronary artery disease (CAD), stroke, and peripheral arterial disease. Atherosclerosis accounts for virtually 80% of all deaths among diabetic patients. Prolonged exposure to hyperglycemia is now recognized a major factor in the pathogenesis of atherosclerosis in diabetes. Hyperglycemia induces a large number of alterations at the cellular level of vascular tissue that potentially accelerate the atherosclerotic process. Animal and human studies have elucidated three major mechanisms that encompass most of the pathological alterations observed in the diabetic vasculature: 1) Nonenzymatic glycosylation of proteins and lipids which can interfere with their normal function by disrupting molecular conformation, alter enzymatic activity, reduce degradative capacity, and interfere with receptor recognition. In addition, glycosylated proteins interact with a specific receptor present on all cells relevant to the atherosclerotic process, including monocyte-derived macrophages, endothelial cells, and smooth muscle cells. The interaction of glycosylated proteins with their receptor results in the induction of oxidative stress and proinflammatory responses 2) oxidative stress 3) protein kinase C (PKC) activation with subsequent alteration in growth factor expression. Importantly, these mechanisms may be interrelated. For example, hyperglycemia-induced oxidative stress promotes both the formation of advanced glycosylation end products and PKC activation.
引用
收藏
页数:10
相关论文
共 76 条
[1]   Molecular basis for a link between complement and the vascular complications of diabetes [J].
Acosta, J ;
Hettinga, J ;
Flückiger, R ;
Krumrei, N ;
Goldfine, A ;
Angarita, L ;
Halperin, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5450-5455
[2]  
*AM DIAB ASS, 1993, DIABETES CARE, V16, P72
[3]   Role of oxidative stress in diabetic complications - A new perspective on an old paradigm [J].
Baynes, JW ;
Thorpe, SR .
DIABETES, 1999, 48 (01) :1-9
[4]   ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].
BAYNES, JW .
DIABETES, 1991, 40 (04) :405-412
[5]   INCREASED COLLAGEN-LINKED PENTOSIDINE LEVELS AND ADVANCED GLYCOSYLATION END-PRODUCTS IN EARLY DIABETIC NEPHROPATHY [J].
BEISSWENGER, PJ ;
MOORE, LL ;
BRINCKJOHNSEN, T ;
CURPHEY, TJ .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :212-217
[6]   TERMINAL COMPLEMENT PROTEINS C5B-9 RELEASE BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR FROM ENDOTHELIAL-CELLS [J].
BENZAQUEN, LR ;
NICHOLSONWELLER, A ;
HALPERIN, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :985-992
[7]   GLYCOSYLATED LOW-DENSITY-LIPOPROTEIN IS MORE SENSITIVE TO OXIDATION - IMPLICATIONS FOR THE DIABETIC PATIENT [J].
BOWIE, A ;
OWENS, D ;
COLLINS, P ;
JOHNSON, A ;
TOMKIN, GH .
ATHEROSCLEROSIS, 1993, 102 (01) :63-67
[8]  
BRETT J, 1993, AM J PATHOL, V143, P1699
[9]   NONENZYMATIC GLYCOSYLATION PRODUCTS ON COLLAGEN COVALENTLY TRAP LOW-DENSITY LIPOPROTEIN [J].
BROWNLEE, M ;
VLASSARA, H ;
CERAMI, A .
DIABETES, 1985, 34 (09) :938-941
[10]   AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING [J].
BROWNLEE, M ;
VLASSARA, H ;
KOONEY, A ;
ULRICH, P ;
CERAMI, A .
SCIENCE, 1986, 232 (4758) :1629-1632